GORE MEDICAL RECEIVES BREAKTHROUGH DEVICE DESIGNATION FOR THE GORE® EXCLUDER® THORACOABDOMINAL BRANCH ENDOPROSTHESIS
CAUTION: Investigational device. Limited by United States law to investigational use.
Apr 12, 2022
Gore Announces First Commercial In-Human Use of GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System for TEVAR in Australia
New delivery system provides controlled and predictable placement of Gore’s highly conformable and time-tested stent graft
FDA Approves GORE® CARDIOFORM Septal Occluder for PFO Closure to Prevent Recurrent Ischemic Stroke
Gore REDUCE Clinical Study demonstrated 77 percent relative reduction in recurrent ischemic stroke when PFO closure was combined with antiplatelet therapy, compared to antiplatelet therapy alone
First Patient Enrolled in Investigational Study of the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System
Investigating the safety and effectiveness of a stent graft system designed to provide endovascular aneurysm repair (EVAR) with angulation control to patients previously considered untreatable
Gore to Highlight Real-World Aortic Data at 45th Annual VEITHsymposium<sup>®</sup>
Company shares findings from the Global Registry for Endovascular Aortic Treatment (GREAT), the largest industry-sponsored registry of aortic stent grafts
Gore Applauds Medicare Announcement to Reclassify Endovascular Abdominal Aneurysm Repairs
Decision comes after two-year effort to improve the alignment of payment with cost of treatment for abdominal aortic aneurysms
Global Vascular Thought Leaders Document Shift toward Individualizing Patient Care in Surgical Bypass
Presentations and Discussions from the Surgical Bypass Summit Available at www.surgicalbypass.com
Gore Recognized as one of the World’s Best Multinational Workplaces by Great Place to Work®
Company earns No 4 spot